Small Business Transition Grant For Early Career Scientists (R41/R42 Clinical Trial Not Allowed)
ID: RFA-CA-24-023Type: Phase I
Overview

Topic

Small Business Transition Grant For Early Career Scientists (R41/R42 Clinical Trial Not Allowed)

Agency

Department of Health and Human ServicesNational Institutes of Health

Program

Type: STTRPhase: Phase IYear: 2024

Topic Link

https://www.sbir.gov/node/2625013

Additional Information

https://grants.nih.gov/grants/guide/rfa-files/RFA-CA-24-023.html
Timeline
    Description

    The Department of Health and Human Services, specifically the National Institutes of Health, is seeking proposals for the Small Business Transition Grant for Early Career Scientists. This grant aims to support early-career academic scientists interested in transitioning to entrepreneurship while also facilitating the transfer of technology from academic laboratories into small businesses. The eligibility for this grant is limited to applicants with 10 years or less of post-graduate experience.

    The grant allows for Phase I only Small Business Technology Transfer (STTR) applications, as well as Fast-Track applications that transition from Phase I STTR to Phase II Small Business Innovation Research (SBIR). The Phase I STTR allows for more work to be completed at the university and provides flexibility in terms of principal investigator (PI) employment. Upon successful completion of Phase I, fast-track applications transition to Phase II as an SBIR award, requiring the PI to move their employment to the small business and limiting university involvement.

    Mentoring is a crucial component of this grant, and a mentoring plan is required in the application. The ideal candidate for this grant is a postdoctoral researcher who has participated in technology discovery during their academic work and is ready to move to a small business with the support of an experienced team.

    Proposed projects must pertain to the mission space of one of the participating Institutes, including the National Cancer Institute, National Institute of Biomedical Imaging and Bioengineering, National Human Genome Research Institute, and National Institute of Mental Health. Each Institute has specific areas of research interest, and applicants are encouraged to contact the Scientific/Research Contacts from the respective Institutes to discuss program relevance.

    The grant has key requirements, including the need for strong mentors, eligibility limited to early-career scientists, and alignment with the scientific/technical scope of the participating Institutes. Additionally, there are specific requirements for each Institute, such as completion of entrepreneurship training programs.

    The transition from Phase I to Phase II is contingent upon meeting certain criteria, including a Phase I final progress report, an updated commercialization plan, updated IP agreements, letters of support from mentors, completion of entrepreneurship programs, and verification of SBIR eligibility.

    The grant provides an opportunity for early-career scientists to transition to entrepreneurship and supports the advancement of technologies from academic research laboratories to small businesses.

    Files
    No associated files provided.
    Similar Opportunities
    Small Business Transition Grant for New Entrepreneurs (R41/R42 Clinical Trial Not Allowed)
    Active
    Department of Health and Human Services
    The Department of Health and Human Services, specifically the National Institutes of Health, is seeking proposals for the Small Business Transition Grant for New Entrepreneurs (R41/R42 Clinical Trial Not Allowed). This grant aims to support early-career scientists and health professionals interested in transitioning to a small business to gain industry experience, receive entrepreneurial training and mentorship, and advance biomedical technology with commercial potential. The grant will provide funding for research and development efforts, as well as the employment and salaries of researchers as Program Directors/Principal Investigators overseeing the supported research project. The grant also emphasizes the importance of mentorship and entrepreneurship training, with applicants required to identify at least one mentor and develop a career development plan for the PD/PI. The grant is open for applications until April 6, 2027, and more information can be found on the grants.gov website.
    Small Business Transition Grant for New Entrepreneurs (R43/R44 Clinical Trial Not Allowed)
    Active
    Department of Health and Human Services
    The Department of Health and Human Services, specifically the National Institutes of Health, is seeking proposals for the Small Business Transition Grant for New Entrepreneurs (R43/R44 Clinical Trial Not Allowed). This grant aims to support early-career scientists and health professionals interested in transitioning to a small business to gain industry experience, receive entrepreneurial training and mentorship, and advance biomedical or public health technology with commercial potential. The grant utilizes the R43/R44 SBIR Award mechanism and supports research and development efforts, as well as the employment and salaries of researchers as Program Directors/Principal Investigators overseeing the project. The grant encourages the inclusion of mentors with extensive entrepreneurial and mentorship experience and requires a career development plan for the PD/PI that includes entrepreneurship training. The eligibility of the contact PD/PI is limited to scientists, engineers, and health professionals who are new to research entrepreneurship and have not independently led significant research programs. The proposed projects must pertain to the mission space of one of the participating Institutes and Centers and fall within the scope of the traditional SBIR/STTR grant mechanisms. The grant is open for applications until April 6, 2027, and more information can be found on the grants.gov website.
    SBIR/STTR Commercialization Readiness Pilot (CRP) Program Technical Assistance and Late Stage Development (SB1, Clinical Trial Not Allowed)
    Active
    Department of Health and Human Services
    The Department of Health and Human Services, specifically the National Institutes of Health, is seeking proposals for the SBIR/STTR Commercialization Readiness Pilot (CRP) Program Technical Assistance and Late Stage Development. This program aims to support the transition of previously funded SBIR/STTR Phase II/IIB projects to the commercialization stage by providing additional support for later stage research and development (R&D) and product development. The program is open to recipients with Phase II or IIB SBIR/STTR awards that have been active within the last 36 months. The program supports technical assistance activities such as regulatory strategy development, intellectual property strategy development, and manufacturing assistance. It also supports late stage research and development activities such as replication of key studies, optimization of manufacturing processes, and development of clinical trial supplies. The program allows for outsourcing of work to third-party technical assistance providers, but the small business should play a substantive role in the oversight and management of the R&D activities. The funding specifics and project duration can be found in the solicitation notice on grants.nih.gov.
    SBIR/STTR Commercialization Readiness Pilot (CRP) Program Technical Assistance and Late Stage Development (SB1, Clinical Trial Not Allowed)
    Active
    Department of Health and Human Services
    The Department of Health and Human Services, specifically the National Institutes of Health, is seeking proposals for the SBIR/STTR Commercialization Readiness Pilot (CRP) Program Technical Assistance and Late Stage Development. This program aims to provide additional support for later stage research and development (R&D) and product development not typically supported through Phase II or Phase IIB grants or contracts. The program is designed to bridge the funding gap between the end of the SBIR/STTR Phase II award and the commercialization stage, often referred to as the "Valley of Death." The program supports new "Type 1" applications from recipients with Phase II or IIB SBIR/STTR awards that have been active within the last 36 months. The program focuses on providing technical assistance and late stage R&D activities, such as regulatory strategy development, intellectual property strategy development, manufacturing assistance, and market research. The program also supports activities related to late stage development, including replication of key studies, optimization of manufacturing processes, animal studies, and development of clinical trial supplies. The program allows for outsourcing of work to third-party technical assistance providers, but the small business should play a substantive role in the oversight and management of the R&D activities. The program does not support clinical trials and cannot be used to pay filing fees for patents or FDA submissions. The program is open for applications until April 6, 2025, and more information can be found on the grants.gov website.
    SBIR/STTR Commercialization Readiness Pilot (CRP) Program Technical Assistance and Late Stage Development (SB1 Clinical Trial Required)
    Active
    Department of Health and Human Services
    The Department of Health and Human Services, specifically the National Institutes of Health, is seeking proposals for the SBIR/STTR Commercialization Readiness Pilot (CRP) Program Technical Assistance and Late Stage Development. This program aims to provide additional support for later stage research and development (R&D) and product development not typically supported through Phase II or Phase IIB grants or contracts. The program is designed to bridge the funding gap between the end of the SBIR/STTR Phase II award and the commercialization stage, often referred to as the "Valley of Death." The program supports projects that require technical assistance and R&D studies that are typically outsourced to contract research organizations (CROs), such as regulatory assistance, IND/IDE enabling studies, toxicology, manufacturing, and clinical trials. The program also supports activities important for commercialization, such as product development, market planning, market research, and costs related to license agreements and partnerships. The program is open to companies that have received Phase II or Phase IIB funding from NIH within the last 36 months. The funding specifics, project duration, and performance goals can be found in the solicitation notice on grants.nih.gov.
    NINDS Exploratory Clinical Trials for Small Business (R41/R42 Clinical Trial Required)
    Active
    Department of Health and Human Services
    The Department of Health and Human Services, specifically the National Institutes of Health, is seeking proposals for the NINDS Exploratory Clinical Trials for Small Business (R41/R42 Clinical Trial Required). This solicitation aims to support small business concerns (SBCs) in conducting exploratory clinical trials that contribute to the justification for future trials to establish definitive efficacy. The trials can include Phase 1 and 2 studies of drugs and biologics, feasibility and preliminary efficacy studies of devices, as well as early studies of surgical, behavioral, or rehabilitation therapies. The trials can be single-site or multi-site with up to three clinical sites. The applications must generate data that inform further clinical development of the proposed intervention or diagnostic, and FDA approval is required for FDA-regulated clinical trials. The goal is to advance products/technologies that require federal regulatory approval or bring complex research tools to market. The funding opportunity is open until September 6, 2026. For more information and to apply, visit the solicitation agency URL: link.
    NINDS Exploratory Clinical Trials for Small Business (R41/R42 Clinical Trial Required)
    Active
    Department of Health and Human Services
    The Department of Health and Human Services, specifically the National Institutes of Health, is seeking proposals for the NINDS Exploratory Clinical Trials for Small Business (R41/R42 Clinical Trial Required). This solicitation aims to support small business concerns (SBCs) in conducting exploratory clinical trials that contribute to the justification for future trials to establish definitive efficacy. The trials can include Phase 1 and 2 studies of drugs and biologics, feasibility and preliminary efficacy studies of devices, as well as early studies of surgical, behavioral, or rehabilitation therapies. The trials can be single-site or multi-site with up to three clinical sites. The applications must generate data that inform further clinical development of the proposed intervention or diagnostic, and FDA approval is required for FDA-regulated clinical trials. The goal is to advance products/technologies that require federal regulatory approval or bring complex research tools to market. The funding opportunity is open until September 6, 2026. For more information and to apply, visit the solicitation agency URL: link.
    SBIR/STTR Commercialization Readiness Pilot (CRP) Program Technical Assistance and Late Stage Development (SB1 Clinical Trial Required)
    Active
    Department of Health and Human Services
    The Department of Health and Human Services, specifically the National Institutes of Health, is seeking proposals for the SBIR/STTR Commercialization Readiness Pilot (CRP) Program Technical Assistance and Late Stage Development. This program aims to provide additional support for later stage research and development (R&D) and product development not typically supported through Phase II or Phase IIB grants or contracts. The program is designed to bridge the funding gap between the end of the SBIR/STTR Phase II award and the commercialization stage, often referred to as the "Valley of Death." The program supports projects that require technical assistance and R&D studies typically outsourced to contract research organizations (CROs), such as regulatory assistance, IND/IDE enabling studies, toxicology, manufacturing, and clinical trials. The program also supports activities important for commercialization, such as product development, market planning, market research, and costs related to license agreements and partnerships. The program is open to companies that have received Phase II or Phase IIB funding from NIH within the last 36 months. The application due dates are September 5, 2023, January 5, 2024, April 5, 2024, September 5, 2024, January 5, 2025, and April 5, 2025. For more information and to apply, visit the solicitation agency URL: link.
    HEAL Commercialization Readiness Pilot (CRP) Program: Embedded Entrepreneurs for Small Businesses in Pain Management (SB1 Clinical Trial Not Allowed)
    Active
    Department of Health and Human Services
    The Department of Health and Human Services, specifically the National Institutes of Health, is seeking proposals for the HEAL Commercialization Readiness Pilot (CRP) Program: Embedded Entrepreneurs for Small Businesses in Pain Management. This program aims to support the commercialization of Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) Phase II or Phase IIb pain management technologies funded by the HEAL Initiative. The program focuses on adding experienced entrepreneurs to small business leadership teams and supporting private fundraising and partnership activities. The goal is to attract private investment and partnerships to accelerate the development and commercialization of innovative pain management products. The program is open for applications until September 6, 2025, and applicants must have received Phase II or Phase IIB funding from NIH. The funding will support the hiring of qualified individuals to fill gaps in business expertise within the small business leadership team and the development of a detailed partnering plan to attract private funding. The program encourages applications from candidates of diverse backgrounds and expects applicants to actively seek private funding or partnering. The proposed activities should be directly related to private fundraising and partnering, such as US-based travel to meet potential partners, legal activities, and business development activities. Applicants are expected to meet with a minimum of ten potential partners fitting the appropriate target profile for the technology and company.
    Late-Stage Translation of Biomedical and Behavioral Research Results in Arthritis and Musculoskeletal and Skin Diseases from Academic/Non-profit Lab to Marketplace (SBIR [R43/R44] Clinical Trial Not Allowed)
    Active
    Department of Health and Human Services
    The Department of Health and Human Services, specifically the National Institutes of Health, is seeking proposals for the late-stage translation of biomedical and behavioral research results in arthritis and musculoskeletal and skin diseases from academic/non-profit labs to the marketplace. This Small Business Innovation Research (SBIR) grant opportunity aims to support the development of diagnostic tools, prevention tools, and treatments for these diseases. The focus is on moving lab technologies towards commercial dissemination through partnerships and close collaboration between small businesses and the original developers of the technologies. The research objectives include late-stage pre-clinical studies on technology or therapy feasibility, as well as studies required for regulatory approval before clinical testing. Clinical trials are excluded from this opportunity. The research topics of interest include the development of therapies, innovative drug delivery strategies, biomarker studies, outcome measures and methodologies, and 3D human tissue models. Collaboration between academic/non-profit labs and small businesses is encouraged, with the academic/non-profit labs performing a portion of the project. The proposal should include milestones with quantitative success criteria to measure the progress and efficacy of the project. Applications that do not originate from academic/non-profit labs or propose intervention studies are not responsive to this opportunity. The grant is open for applications until September 6, 2025. For more information, visit the solicitation agency URL: link.